Jason A. ZellAssistant Professor, Medicine Assistant Professor, Epidemiology Associate Program Director, Hematology/Oncology Fellowship Training Program, Medicine |
|
|
Research Interests |
Colorectal Cancer, Gastrointestinal Oncology, Cancer Prevention, Genetic Epidemiology | |
| URLs | Div. of Hematology/Oncology - Dept. of Medicine | |
| Dept. of Epidemiology - School of Medicine | ||
|
Academic Distinctions | Cum Laude, UCSB (1994); Northwest Osteopathic Medical Foundation-Scholarship Recipient (1999); NSU Family Medicine/Master of Public Health-Scholarship Receipient (1999-2001); Graduate with Honors, Nova Southeastern University (NSU)-COM (2001); Graduate with Highest Honors, NSU-Master of Public Health Program; Psi Sigma Alpha National Scholastic Osteopathic Honors Society (2001); UCI Department of Medicine, Internal Medicine Resident of the Year (2002-2003,PGY-2 Class), Delta Omega National Public Health Honor Society, Nova Southeastern University, Alpha XI Chapter (2005); 11th World Conference on Lung Cancer-Travel Award Recipient (Barcelona, Spain 2005); AACR Colorectal Cancer Conference-Scholar in Training Award (Dana Point, CA 2005); National Lung Cancer Partnership-Travel Award Recipient (Atlanta, GA 2005); 2007 Annual Conference Poster Session, NAACCR-First Place-Epidemiologic Studies (Detroit, MI 2007); 12th World Conference on Lung Cancer, IASLC-Young Investigator Award (Seoul, Korea 2007); Southwest Oncology (SWOG) Young Investigator Award(Seattle, WA 2008). | |
|
Research Abstract |
Dr. Zell's research focusses on the prevention and treatment colorectal cancer. He has served as a translational oncology researcher and faculty member at the UC Irvine Chao Family Comprehensive Cancer Center since 2007. Dr. Zell receives extramural research funding from the U.S. National Institutes of Health (NIH) to perform genetic epidemiology-based colorectal cancer research, and is principle investigator or co-investigator for several NIH-funded phase II prevention clinical trials involving patients with colorectal cancer. Within the National Cancer Institute (NCI)-supported SWOG, Dr. Zell is the Cancer Control & Prevention Liaison to the Gastrointestinal Committee. Additionally, he is national principle investigator for S0820, a large multicenter randomized phase III trial involving risk reduction among resected colon cancer patients that is supported by the NIH-Division of Cancer Prevention, and conducted by SWOG. | |
| Publications |
1) Ramakrishnan R, Zell JA, Malave A, Rathinavelu A. Expression of vascular endothelial growth factor mRNA in GI-101A and HL-60 cell lines. Biochem Biophys Res Commun. 2000 Apr 21;270(3):709-13. PMID: 10772888 2) O'Rourke A, Zell JA*, Varkey-Zell TT, Barone JL, Bayona M. Laparoscopic diagnosis and repair of asymptomatic bilateral inguinal hernias. Am J Surg. 2002 Jan 183(1):15-9. PMID: 11869696 3) Zell JA, Ramakrishnan R, Rathinavelu A. Regulation of mdm2 mRNA expression in human breast tumor-derived GI-101A cells. Life Sci. 2002 Oct 4;71(20):2331-9. PMID: 12231395 4) Canetti M, Akhter MW, Lerman A, Karaalp IS, Zell JA, Singh H, Mehra A, Elkayam U. Evaluation of myocardial blood flow reserve in patients with chronic congestive heart failure due to idiopathic dilated cardiomyopathy. Am J Cardiol. 2003 Nov 15;92(10):1246-9. PMID: 14609613 5) Bokhari, SW, Bokhari, ZW, Zell, JA, Lee, DW, Faxon, DP. Plasma homocysteine levels and the left ventricular systolic function in coronary artery disease patients. Coronary Artery Disease 2005 May 16(3);153-161. PMID: 15818084 6) Zell, JA*, Ou, S-HI, Ziogas, A, Anton-Culver, H. Epidemiology of bronchioloalveolar carcinoma: improvement in survival after release of the 1999 WHO classification of lung tumors. J Clin Oncol 2005 Nov 23(33):8396-8405. PMID: 16293870 7) Zell, JA*, Ou, S-HI, Ziogas, A, Anton-Culver, H. Long-term survival differences for bronchioloalveolar carcinoma patients with ipsilateral intrapulmonary metastasis at diagnosis. Ann Oncol 2006 Aug, 17(8):1255-1262. PMID: 16766595 8) Raz, DJ, Zell, JA, Karnezis, AN, Odisho A, Ou, S-HI, Anton-Culver, H, Jablons DM. Misclassification of bronchioloalveolar carcinoma with cytologic diagnosis of lung cancer. J Thor Oncol 2006 Nov, 1:943-948. PMID: 17409976 9) Ou, S-HI, Zell, JA, Ziogas, A, Anton-Culver, H. Epidemiology of nasopharyngeal carcinoma in the United States: improved survival of Chinese patients within the keratinizing squamous cell carcinoma histology. Ann Oncol 2007 Jan;18(1):29-35. Epub 2006 Oct 23. PMID: 17060483 10) Zell, JA*, Ignatenko, NA, Yerushalmi, H, Ziogas, A, Besselsen, DG, Gerner, EW, Anton-Culver, H. Risk and risk reduction involving arginine intake and meat consumption in colorectal tumorigenesis and survival. Int J Cancer 2007 Feb, 120(3):459-468. PMID: 17096347 11) Zell, JA*, Rhee, JM, Ziogas, A, Lipkin, SM, Anton-Culver, H. Race, socioeconomic status, treatment, and survival time among pancreatic cancer cases in California. Cancer Epi Biomarkers & Prevention 2007 March, 16(3):546-552. PMID: 17372250 12) Raz, DJ, Zell, JA, Ou, S-HI, Gandara, DR, Anton-Culver, H, Jablons DM. Natural history of stage I NSCLC: poor survival of untreated patients and implications for early detection. Chest, 2007 July, 132:193-199. PMID: 17505036 13) Ou, S-HI, Zell, JA, Ziogas, A, Anton-Culver, H. Prognostic factors for survival of stage I non-small cell lung cancer (NSCLC) patients: a population-based analysis of 19,702 stage I patients in the California Cancer Registry (CCR) from 1989 to 2003. Cancer 2007 Oct 1; 110(7):1532-41. PMID: 17702091 14) Zell, JA*, McEligot, A, Ziogas, A, Holcombe, RF, Anton-Culver, H. Differential effects of wine consumption on colorectal cancer outcomes based on family history of the disease. Nutrition & Cancer, 2007 Oct. Volume 59(1): 36-45. PMID: 17927500 15) Ou, S-HI, Zell, JA, Ziogas, A, Anton-Culver, H. Prognostic significance of the non-size based AJCC T2 descriptors: visceral pleura invasion (VPI), hilar atelectasis or obstructive pneumonitis in stage IB non-small-cell lung cancer (NSCLC) is dependent on tumor size. Chest, 2008 March, 133: 662-669; [Epub ahead of print Oct 9, 2007]; PMID: 17925418. 16) Zell, JA*, Ou, S-HI, Ziogas, A, Anton-Culver, H. Survival Improvements for Advanced Stage non-Bronchioloalveolar Carcinoma-type Non-Small-Cell Lung Cancer Cases with Ipsilateral Intrapulmonary Metastasis. Cancer, 2008 January, 112 (1): 136-143. PMID: 17960795 17) Zell, JA*, Ou, S-HI, Ziogas, A, Anton-Culver, H. Validation of the Proposed International Association for the Study of Lung Cancer Non-small Cell Lung Cancer Staging System Revisions for Advanced Bronchioloalveolar Carcinoma Using Data from the California Cancer Registry. J Thor Oncol, 2007 Dec, 2(12): 1078-1085. PMID: 18090578 18) Zell, JA*, Cinar, P, Mobasher, M, Ziogas, A, Meyskens, FL, Anton-Culver, H. The effects of race, socioeconomic status, and treatment on survival for invasive cutaneous melanoma cases. J Clin Oncol, 2008 Jan, 26(1): 66-75. PMID: 18165642 19) Ou, S-HI, and Zell, JA* Validation study of the proposed IASLC staging revisions of the T4 and M Non-Small Cell Lung Cancer descriptors using data from 23,583 patients in the California Cancer Registry. J Thor Oncol, 2008, March, Vol 3 (3): 216-227. PMID: 18317063 20) Ou, S-HI, Zell, JA, Ziogas, A, Anton-Culver, H. Low socioeconomic status is a poor prognostic factor for survival in stage I non-small-cell lung cancer and is independent of surgical treatment, race, and marital status. Cancer, 2008, May 1, 112(9):2011-2020. PMID: 18361399 21) Narasimhan, M, Rose, R, Ramakrishnan, R, Zell, JA, Rathinavelu, A. Identification of HDM2 as a regulator of VEGF expression in cancer cells. Life Sci. 2008 Jun 18;82(25-26):1231-41. PMID: 18504050 22) Ou, S-HI, Zell, JA Prognostic significance of the number of lymph nodes removed at lobectomy in stage IA non-small cell lung cancer (NSCLC). J Thor Oncol, 2008, August, Vol 3(8):880-886. PMID: 18670306 23) Le, H, Ziogas, A, Lipkin, SM, Zell, JA* Effects of socioeconomic status and treatment disparities in colorectal cancer survival. Cancer Epi Biomarkers & Prev, 2008, August, Vol. 17(8): 1950-1952. PMID: 18708384 24) Le, H, Rhee, JM, Ziogas, A, Lee, JG, Lipkin, SM, Zell, JA* A population-based, descriptive analysis of malignant intraductal papillary mucinous neoplasms (IPMNs) of the pancreas Cancer Epi Biomarkers & Prev, 2008, October, Vol 17(10): 2737-2741. PMID: 18843017 25) Zell, JA*, Honda, J, Ziogas, A, Anton-Culver, H. Survival after Colorectal Cancer Diagnosis is Associated with Colorectal Cancer Family History Cancer Epi Biomarkers & Prevention, 2008, November 17(11): 3134-3140. PMID: 18990755 26) Le, H, Ziogas, A, Taylor, TH, Lipkin, SM, Zell, JA* Survival of distinct Asian groups among colorectal cancer cases in California Cancer, 2009, January 115 (2):259-270. PMID: 19109815 27) Ou, S-HI, Ziogas, A, Zell, JA Prognostic factors for survival in extensive stage small cell lung cancer (ED-SCLC): the importance of smoking history, socioeconomic and marital statuses, and ethnicity J Thor Oncol, 2009, January, 4(1):37-43. PMID: 19096304 28) Ou, S-HI, Zell, JA The applicability of the proposed IASLC staging revisions to small cell lung cancer (SCLC) with comparison to the current AJCC 6th TNM edition J Thor Oncol, 2009, March, 4(3): 300-309. PMID: 19156001 29) Wray, C, Hinojosa, MW, Ziogas, A, Le, H, Stamos, MJ, and Zell, JA* Tumor subsite location within the colon is prognostic for survival after colon cancer diagnosis Dis Colon Rectum, 2009 Aug;52(8):1359-66. PMID: 19617745 30) Zell, JA*, Pelot, D, Chen, W-P, McLaren, CE, Gerner, EW, Meyskens, FL Risk of Cardiovascular Events in a Randomized Placebo-Controlled, Double-Blind Trial of Difluoromethylornithine Plus Sulindac for the Prevention of Sporadic Colorectal Adenomas Cancer Prevention Research, 2009 Mar;2(3):209-12. PMID: 19258540 31) Zell, JA*, Tsang, W, Taylor, TH, Mehta, RS, Anton-Culver, H. Prognostic impact of tumor receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC cases in the California Cancer Registry Breast Cancer Research, 2009, 11:R9 doi:10.1186/bcr2225, Published 19 February 2009. PMID: 19228416 (“Highly Accessed” article designation) 32) Zell, JA*, Ziogas, A, Bernstein, L, Clarke, CA, Deapen, D, Largent, JA, Neuhausen, SL, Stram, DO, Ursin, G, Anton-Culver, H. Non-steroidal anti-inflammatory drugs: effects on mortality after colorectal cancer diagnosis Cancer, 2009, 115(24):5662-5671. PMID: 19827153 33) Zell, JA*, Ziogas, A, Ignatenko, N, Honda, J, Qu, N, Bobbs, AS, Neuhausen, SL, Gerner, EW, Anton-Culver, H. Associations of a polymorphism in the ornithine decarboxylase gene with colorectal cancer survival. Clinical Cancer Research, 2009, 15(9):6208-6216. PMID: 19789310 34) Ou, S-HI, Ziogas, A, Zell, JA. Asian ethnicity is a favorable prognostic factor for overall survival in non-small-cell lung cancer (NSCLC) and is independent of smoking status. J Thorac Oncol. 2009 Sep;4(9):1083-93. PMID: 19652625 35) Ou, S-HI, Zell, JA. Carcinoma NOS is a common histologic diagnosis and is increasing in proportion among non-small-cell lung cancer histologies. J Thor Oncol, 2009, 4(10):1202-1211. PMID: 19701111 36) Lee, J, Hoang, BH, Ziogas, A, Zell, JA* Analysis of prognostic factors in Ewing sarcoma using a population-based cancer registry. Cancer. 2010, Apr 15; 116(8):1964-73. PMID: 20151425 37) Ou, S-HI, Ziogas, A, Zell, JA. A Comparison Study of Clinicopathologic Characteristics of Southern California Asian American Non-small Cell Lung Cancer (NSCLC) Patients by Smoking Status. J Thorac Oncol. 2010 Feb;5(2):158-68. PMID: 20040896 38) Ou, S-HI, Ziogas, A, Zell, JA. Primary signet-ring cell carcinoma (SRCC) of the lung. A population-based epidemiologic study of 262 cases with comparison to adenocarcinoma of the lung. J Thorac Oncol. 2010 Apr;5(4):420-7. PMID: 20130484 39) Zell, JA*, Ziogas, A, Bernstein, L, Clarke, CA, Deapen, D, Largent, JA, Neuhausen, SL, Stram, DO, Ursin, G, Anton-Culver, H. Meat consumption, non-steroidal anti-inflammatory drugs, and mortality among colorectal cancer patients in the California Teachers Study. Cancer Prevention Research, 2010 Jul;3(7):865-75. PMID: 20551290 40) Kawaguchi T, Matsumura A, Fukai S, Tamura A, Saito R, Zell JA, Maruyama Y, Ziogas A, Kawahara M, Ignatius Ou SH. Japanese Ethnicity Compared with Caucasian Ethnicity and Never-Smoking Status Are Independent Favorable Prognostic Factors for Overall Survival in Non-small Cell Lung Cancer: A Collaborative Epidemiologic Study of the National Hospital Organization Study Group for Lung Cancer (NHSGLC) in Japan and a Southern California Regional Cancer Registry Databases. J Thorac Oncol. 2010 Jul;5(7):1001-10. PMID: 20526205 41) Largent, JA, Bernstein, L, Horn-Ross, PL, Marshall, SF, Neuhausen, S, Reynolds, P, Ursin, G, Zell, JA, Ziogas, A, Anton-Culver, H. Hypertension, antihypertensive medication use, and breast cancer risk in the California Teachers Study cohort. Cancer Causes Control. 2010 Oct;21(10):1615-24. Epub 2010 Jun 6. PMID: 20526803 42) Ahn, M-J, Lee, J, Park, Y-H, Ahn, J-S, Ziogas, A, Zell, JA, Park, K, Ou, S-HI. Korean ethnicity as compared to Caucasian ethnicity is an independent favorable prognostic factor for overall survival in NSCLC before and after the oral EGFR TKI era. J Thorac Oncol. 2010 Aug;5(8):1185-96 PMID: 20592628 43) Thompson, PA, Wertheim, BC, Zell, JA, Chen, W-P, McLaren, CE, Meyskens, FL, Gerner, EW. Rectal mucosal polyamine and prostaglandin E2 levels and risk of colorectal adenoma in a phase IIb/III trial of combination difluoromethylornithine plus sulindac. Gastroenterology, 2010 Sep;139(3):797-805.e1. PMID: 20538001 44) Zell, JA*, McLaren, CE, Chen, W-P, Thompson, PA, Gerner, EW, Meyskens, FL. Ornithine decarboxylase-1 polymorphism, chemoprevention with eflornithine and sulindac, and outcomes among colorectal adenoma patients. Journal of the National Cancer Institute. 2010 Oct 6;102(19):1513-6. Epub 2010 Aug 26. PMID: 20798393. 45) Katz, MH, Taylor, TH, Al-Refaie, WB, Hannah, M, Imagawa, DK, Anton-Culver, H, and Zell, JA. Adenosquamous versus adenocarcinoma of the pancreas: a population-based outcomes analysis J Gastrointest Surg. 2011 Jan;15(1):165-74. PMID: 21082275 46) Bessonova, L, Taylor, TH, Mehta, RS, Zell,JA, Anton-Culver, H. Risk of a Second Breast Cancer Associated with Hormone-Receptor and HER2/neu Status of the First Breast Cancer. Cancer Epi Biomarkers Prev, 2011 Feb;20(2):389-96. Epub 2011 Jan 7. PMID:21217087 47) Lipkin, S, Lee, J, Imagawa, D, Hewitt, SM, Tucker, C, Zell, JA, Wong, V, Garcia, A, Gonzalez, R, Della-Zanna, G, Richmond, E, Rodriguez, LM, and Meyskens, FL Phase IIA Trial Testing Erlotinib as an Intervention Against Intraductal Pancreatic Mucinous Neoplasms. Cancer Prev Res 2011;4:512-513. PMID: 21464031 48) Pan, C-JG, Ziogas, A, Buchberg, B, Raj, KP, Mills, SD, Stamos, MJ, Zell, JA*. Timing of radiation therapy, lymph node retrieval, and survival in rectal cancer. Dis Colon & Rectum, 2011, 54(5):526-34. PMID: 21471752 49) Raj, KP, Taylor, TH, Wray, C, Stamos, MJ, Zell, JA*. Risk of Second Primary Colorectal Cancer among Colorectal Cancer Cases: a population-based analysis. Journal of Carcinogenesis 2011;10:6. PMID:21483654 50) Lee J, Bhatia NN, Hoang BH, Ziogas A, Zell, JA*. Analysis of prognostic factors for patients with chordoma with use of the California cancer registry. J Bone Joint Surg Am. 2012 Feb 15;94(4):356-63. PMID: 22336975 [PubMed - in process] Reviews, Letters, Editorials, & Case Reports 1) Zell, JA*, Yoon, EJ, Ou, S-HI, Hoefs, JC, Chang, JC. Precore mutant hepatitis B reactivation after CHOP-rituximab. Anticancer Drugs. 2005 Jan 16(1); 83-85. PMID: 15613909 2) Zell, JA*, Chang JC. Neoplastic fever: a neglected paraneoplastic syndrome. Supportive Care in Cancer 2005 Nov 13(11):870-877. Review. PMID: 15864658 3) Zell, JA*, Ou, S-HI, Ziogas, A, Anton-Culver, H. In Reply. J Clin Oncol 2006 April, 24(12):1963-1964. 4) Zell, JA*, Iyer, P, Kukes, G, Beamon, D. An unusual case of renal carcinoma. Pathology 2006 Aug, 38(4):370-371. PMID: 16916734 5) Ou, S-HI, and Zell, JA. Response. Chest. 2008 Sep;134(3):674. 6) Raj, K, Sanati, H, Mehta, RS, and Zell, JA Need for a New Treatment Strategy: Leptomeningeal Carcinomatosis due to Gastric Cancer. Anticancer Drugs 2009 Apr;20(4):301-4. PMID: 19247177 7) Ou, S-HI, and Zell, JA. Response. Chest. 2009 June; 135:1695-1696. 8) Zell, JA*, and Ou, S-HI Survival prognostication in non-small cell lung cancer. (Invited Editorial). J Thorac Oncol. 2009 Jul;4(7):785-6. PMID: 19550241 9) Zell, JA*, Madson, N, and Meykens, FL New chemoprevention for colorectal cancer. Principles & Practice of Oncology Updates, 2009 July; 23(4):1-8. 10) Ou, S-HI, Zell, JA In Response J Thor Oncol. 4(8):1041-1042, August 2009. 11) Timberlake, DS, and Zell, JA Review of epidemiologic data on the debate over smokeless tobacco's role in harm reduction. (Invited Editorial) BMC Med. 2009 Oct 19;7:61. Review. PMID: 19840371 12) Zell, JA*. Clinical Trials Update: Tertiary Prevention of Colorectal Cancer J Carcinog 2011;10:8. PMID: 21483656 |
|
|
Book Chapters: Zell, JA and Meyskens, FL. Chapter 27: Cancer Prevention, Screening, and Early Detection. In Abeloff, Clinical Oncology, 4th ed. Churchill Livingstone, An Imprint of Elsevier, May 2008. Zell, JA. Arginine and Cancer. In Encyclopedia of Cancer 2nd ed. Springer-Verlag, 2009. ISBN: 978-3-540-36847-2 |
||
| Grants | NIH-NCI N01-CN-35160; April 12, 2010-March 12 2012 Protocol UCI 09-13-01 “A Phase IIa Trial of Metformin for Colorectal Cancer Risk Reduction among Patients with a History of Colorectal Adenomas and Elevated Body Mass Index” (Protocol P.I.) | |
| Southwest Oncology Group (SWOG) & The Hope Foundation. Charles Coltman Fellowship Award. July 1st, 2009-June 30, 2011. | ||
| NIH-NCI K23 CA133142 (PI) Aug 20, 2009-Jul 31, 2013 “Risk reduction through polyamine inhibition among colorectal carcinoma patients” | ||
|
Professional Societies |
American Board of Internal Medicine (ABIM) American Association for Cancer Research (AACR) American Society of Hematology (ASH) American Society of Clinical Oncology (ASCO) Southwest Oncology Group (SWOG) American Society of Preventive Oncology (ASPO) |
|
| Other Experience |
Faculty Member U.S. National Cancer Institute - Middle East Cancer Consortium (MECC), Istanbul, Turkey 2007 |
|
|
Diplomat (Board Certified) American Board of Internal Medicine, Internal Medicine 2004 |
||
|
Diplomat (Board Certified) American Board of Internal Medicine, Medical Oncology 2008 |
||
|
Board Certified, American Board of Internal Medicine, Hematology 2010 |
||
|
Co-Leader, Colon Cancer Disease Oriented Team (DOT) Chao Family Comprehensive Cancer Center 2012 |
||
| Graduate Programs |
Epidemiology |
|
| Research Centers | UCI Genetic Epidemiology Research Institute (GERI) | |
| Chao Family Comprehensive Cancer Center | ||
| Institute for Clinical & Translational Sciences | ||
| Link to this profile | http://www.faculty.uci.edu/profile.cfm?faculty_id=5483 | |
| Last updated | 02/27/2012 | |